AstraZeneca Newsroom

Express News | Tracer Biotechnologies Announces Multi-Year Project With AstraZeneca

Benzinga14:02 ET

Tracer Biotechnologies Announces Agreement for Next-Generation Cancer Monitoring for Drug Development

Businesswire14:00 ET

Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study

Zacks Dec 12 08:00 ET

TD Cowen Maintains AstraZeneca(AZN.US) With Buy Rating, Announces Target Price $95

Moomoo NewsDec 12 00:33 ET · Ratings

TD Cowen Keeps Their Buy Rating on AstraZeneca (AZN)

TipRanksDec 12 00:15 ET · Ratings

AstraZeneca (AZN.US) and MSD (MRK.US) announce long-term results from phase 3 Olympia clinical trial

Lynparza is a “first-in-class” PARP inhibitor and the first synthetic lethal targeted therapy to target cells/tumors with homologous recombinant repair (HRR) defects (such as cells carrying BRCA1 and/or BRCA2 mutations).

Zhitong FinanceDec 11 18:56 ET

AstraZeneca, Merck Report Positive Long-term Data for Lynparza

Seeking AlphaDec 11 14:04 ET

AstraZeneca Says 87.5% of Lynparza-treated Patients Alive at Six Years in Trial

TipRanksDec 11 10:25 ET

Express News | Lynparza Shows Significant Survival Benefit In Early Breast Cancer In OlympiA Phase III Trial; Reduces Risk Of Death By 28% And Recurrence By 35% At Six Years, Becoming First PARP Inhibitor To Improve Survival In Early Breast Cancer

BenzingaDec 11 10:16 ET

LYNPARZA (Olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase III Trial

BusinesswireDec 11 10:15 ET

Lynparza Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase III Trial

AstraZeneca Dec 11 00:00 ET

Why Astrazeneca (AZN) Is a Top Value Stock for the Long-Term

Yahoo FinanceDec 10 09:40 ET

AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC

Zacks Dec 10 09:05 ET

AstraZeneca (AZN) Receives a Hold From Jefferies

TipRanksDec 10 02:36 ET · Ratings

Astrazeneca (AZN.US) has achieved breakthrough therapy designation for a potential blockbuster ADC.

Astrazeneca (AZN.US) has a potential blockbuster ADC that has been granted breakthrough therapy designation.

Zhitong FinanceDec 10 01:10 ET

Merck Reports Mixed Results From Keytruda Ovarian Cancer Study

Seeking AlphaDec 9 10:32 ET

Astrazeneca, Daiichi Sankyo's Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in US

MT NewswiresDec 9 07:47 ET

AZN's Bladder Cancer SBLA for Imfinzi Gets FDA's Priority Tag

Zacks Dec 9 07:30 ET

ASH 2024: AstraZeneca Set to Take a BiTE Out of Follicular Lymphoma Market

Yahoo FinanceDec 9 06:37 ET

Priority FDA Review Given to AstraZeneca's Imfinzi SBLA for MIBC

Yahoo FinanceDec 9 04:22 ET